Today: 21 July 2026
Browse Category

Pharmaceuticals 11 May 2026 - 5 June 2026

Oculis Stock Shock: Eye-Drop Trial Miss Sends Shares Sliding

Oculis Stock Shock: Eye-Drop Trial Miss Sends Shares Sliding

Oculis Holding AG shares fell sharply on Friday after the Swiss eye-drug developer said two late-stage trials of its OCS-01 eye drops failed to meet their main goal in diabetic macular edema, a diabetes-linked swelling in the retina that can damage sight. The company said it does not currently plan to pursue a U.S. Food and Drug Administration filing for the drug in that indication.
30 May 2026
··
Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant shares closed 35.3% higher at $35.56 on Wednesday after the biotech company reported encouraging 16-week data for its experimental rheumatoid arthritis drug, IMVT-1402, a move that made the stock one of the day’s standout U.S. healthcare gainers. Roivant Sciences, Immunovant’s majority owner, also rose sharply, closing about 14.9% higher at $32.41.
20 May 2026
···
Pfizer Inc Looks to India, but Investors Hold Off

Pfizer Inc Looks to India, but Investors Hold Off

Pfizer Inc is looking to expand in India, focusing on cancer drugs, obesity therapies, vaccines and other specialty medicines as it looks to get back on track after its COVID-19 sales surge faded. Meenakshi Nevatia, who heads Pfizer in India, called the country a “must-win” and said “no company can be global if they’re not winning.” Nevatia also pointed to the need for faster product launches and better pricing for the Indian market.
15 May 2026
·
Ernexa Stock’s 58% Jump Shows How Fast a Tiny Biotech Can Reprice on Ovarian-Cancer Hopes

Ernexa Stock’s 58% Jump Shows How Fast a Tiny Biotech Can Reprice on Ovarian-Cancer Hopes

Ernexa Therapeutics shot higher on Tuesday, though the trading action left plenty of questions. The move was really a textbook biotech squeeze, sparked by fresh investor focus on ERNA-101, their preclinical cell therapy for ovarian cancer. The stock’s thin float and last month’s reverse split set the stage. As of 3:50 p.m. ET, shares were changing hands at $11.43, marking a gain of 58.5%. ERNA swung as high as $15.58, with an intraday floor at $6.86.
12 May 2026
··
Terns Pharmaceuticals stock stops trading as Merck’s $53 cash deal takes over the chart

Terns Pharmaceuticals stock stops trading as Merck’s $53 cash deal takes over the chart

Terns Pharmaceuticals shares aren’t budging—not surprising, since the merger is done and Nasdaq trading is finished. The last quote for the stock came in at $52.95, just shy of Merck’s $53-per-share cash deal. With Terns now fully absorbed into Merck, its common stock has dropped off the Nasdaq Global Select Market and won’t trade again.
12 May 2026
····
1 2 3 4 5 6 … 44
Go toTop